|
A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients Clinical research trials and A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients. A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients
A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients
For Condition: Secondary Hyperparathyroidism,End Stage Renal Disease
Status: Completed
Sponsor(s): Amgen ,
Synopsis: This 6 month long study will assess an investigational medication for patients on dialysis with secondary hyperparathyroidism. The study will look at the effects on parathyroid hormone, calcium and phosphorus levels.
Details:
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: - Patients must be receiving hemodialysis; - Have elevated parathyroid hormone levels; - Not be pregnant or nursing; and - Not have had a heart attack in the last 3 months.
Total Enrollment:
Location and Contact Information:
Research Center
Portland, Oregon,
United States
Research Site
Birmingham, Alabama,
United States
Research Center
San Diego, California,
United States
Research Center
Rochester, New York,
United States
Research Center
Las Vegas, Nevada,
United States
Research Center
Norwood, Ohio,
United States
Research Center
Asheville, North Carolina,
United States
Research Site
Chicago, Illinois,
United States
Research Center
Walnut Creek, California,
United States
Research Center
Thornton, Colorado,
United States
Research Center
Des Moines, Iowa,
United States
Research Center
Chapel Hill, North Carolina,
United States
Research Center
Rockville, Maryland,
United States
Research Center
St. Louis, Missouri,
United States
Research Center
Cincinnati, Ohio,
United States
Research Center
Boston, Massachusetts,
United States
Research Center
Philadelphia, Pennsylvania,
United States
Research Center
Denver, Colorado,
United States
Research Center
Miami, Florida,
United States
Research Center
Nashville, Tennessee,
United States
Additional Information:
Study ID Numbers: 20000172;
Study Start Date:
Record last reviewed: January 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00037635
Other End Stage Renal Disease Studies:
1. Safety and Effectiveness of Zemplar Injection in decreasing iPTH levels in pediatric ESRD subjects on hemodialysis
2. A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients
3. A Study of an Investigational Medication for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients
4. A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis
Related Studies:
Other End Stage Renal Disease Clinical Trials
Other Missouri Clinical Trials
Other St. Louis Clinical Trials
A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients
|
|
|
|
|
|
|
|